APVO Stock Risk & Deep Value Analysis

Aptevo Therapeutics Inc

DVR Score

1.0

out of 10

Distressed

The Bottom Line on APVO

We analyzed Aptevo Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran APVO through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Mar 21, 2026•Run Fresh Analysis →

📈APVO Performance Overview3yr weekly

📊

Unlock APVO Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

APVO Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

High

Market Risk

High

APVO Deep Value Analysis

Aptevo Therapeutics' ADAPTIR™ platform continues to target a significant oncology market. However, the reported $0.00B market cap, despite the company still trading, signifies near-total destruction of shareholder value since the last analysis. While the company has technically survived past its critical Q1 2024 cash runway (implying capital raises), this appears to have come at an extreme cost, likely through massive dilution. This severely undermines any realistic 10x growth potential for existing shareholders. Intense competition, continued high burn rate, and lack of substantial, value-creating clinical progress further contribute to an unsustainable trajectory. The fundamental financial red flags continue to overshadow theoretical scientific potential, rendering it an extremely high-risk, practically non-viable investment for growth.

APVO Red Flags & Warning Signs

Premium

⚠
Further highly dilutive capital raises
⚠
Clinical trial failures or significant delays
⚠
Continued high cash burn leading to another liquidity crisis
⚠
Reverse stock split to maintain listing compliance
⚠
Delisting from exchange or bankruptcy proceedings

Unlock APVO Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

APVO Competitive Moat Analysis

Premium

Moat Rating

None

Moat Trend

Eroding

Moat Sources

1 Identified

Intangible Assets/IP (in the form of proprietary platform and early-stage drug candidates, but highly vulnerable without commercialization or strong funding)

The proprietary technology is not yet proven to be commercially viable or superior in a highly competitive market, especially without sufficient funding for advanced clinical development. The 'moat' is theoretical and highly fragile.

APVO Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

APVO Catalysts & Growth Drivers

Near-Term (0-6 months)

•Q4 2025 / Full Year 2025 earnings report (expected late Q1/early Q2 2026)
•Q1 2026 earnings report (expected early-May 2026)
•Any update on early-stage clinical trials (e.g., APVO436 Phase 1)

Medium-Term (6-18 months)

•Potential new financing round (likely dilutive)
•Initiation of new clinical trials for pipeline candidates (highly optimistic scenario)
•Minor strategic collaboration (unlikely to be value-transforming)

Long-Term (18+ months)

•Major breakthrough clinical data that attracts a large pharmaceutical partner or acquisition (extremely low probability)
•Successful regulatory approval of a lead drug candidate (decades away, if ever)

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

APVO Bull Case: What Could Go Right

✓
Announcement of a significant, non-dilutive strategic partnership with substantial upfront payments
✓
Release of robust, late-stage positive clinical data demonstrating clear superiority over existing treatments
✓
A major management overhaul with new leadership bringing significant capital infusion and a clear, viable commercialization strategy.

Bull Case Analysis

See what could go right with Premium

🔔

Never miss a move on APVO

Create a free account to set price alerts and get notified on Telegram when APVO hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Aptevo Therapeutics Inc (APVO)?

As of March 21, 2026, Aptevo Therapeutics Inc has a DVR Score of 1.0 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the risk level for APVO stock?

Our analysis rates Aptevo Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

How often is the APVO DVR analysis updated?

Our AI-powered analysis of Aptevo Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 21, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.